TABLE 4.

Antibody inactivation studies of CMY-2 β-lactamase with peptidea

β-lactamase/substratePeptide:antibody:β-lactamase molar ratioVelocity (μM−1 s−1)% Decrease
Pep:anti-CMY-2:CMY-2
3.5 nM CMY-2/Cefaz5,000:0:11.0 ± 0.02
3.5 nM CMY-2/Cefaz0:0:11.1 ± 0.030
3.5 nM CMY-2/Cefaz0:10:10.4 ± 0.0560
3.5 nM CMY-2/Cefaz5,000:10:10.3 ± 0.0770
Pep:anti-CMY-2:CMY-2
18 nM CMY-2/NCF5,000:0:14.0 ± 0.1
18 nM CMY-2/NCF0:0:13.6 ± 0.0310
18 nM CMY-2/NCF0:10:11.5 ± 0.0163
18 nM CMY-2/NCF5,000:10:11.4 ± 0.0465
  • a β-Lactamase was mixed with various molar ratios of anti-CMY-2 antibody, as described in Materials and Methods. Each velocity determination was repeated in triplicate, and standard deviations were calculated. Pep, synthetic peptide V211-V223 of CMY-2 β-lactamase. NCF, 100 μM nitrocefin; Cefaz, 50 μM cefazolin. Percent decrease is relative to the velocity determined when no antibody was added.